Genome&Company joins global pharma Lilly's TuneLab; accelerating AI drug development
Predicted impact: Low
Lilly TuneLab participation already reported several times; no financial terms given
Genome&Company지놈앤컴퍼니
314130 · KOSDAQ · ₩314130 · 지놈앤컴퍼니
₩3,505▼ ₩135 (3.71%)End-of-day · Oct 30, 2026 · End-of-day prices.
Genome&Company acquires management rights of K-beauty distributor Allbloom, expanding US reach of 'Yuik'
Predicted impact: Low
Management rights acquisition of small distributor; size is small versus market value.
Genome&Company Acquires Cosmetics Distributor Allbloom, Accelerates Eulyc's U.S. Expansion
Predicted impact: Medium
Acquisition of a cosmetics distributor; deal size undisclosed but small versus revenue.
"Cutting Drug Development Costs" GenomeAndCompany Joins Lilly's AI Platform 'TuneLab'
Predicted impact: Low
Joining Lilly's AI drug platform is a partnership with no disclosed deal size; repeats earlier coverage.
Genome & Company Joins Lilly TuneLab, Advancing AI-Based New Drug Development
Predicted impact: Low
Partnership with Lilly TuneLab for AI drug development; no deal value disclosed.
Genome & Company joins Lilly's AI drug development platform, aiming to speed up candidate optimization
Predicted impact: Medium
Joins Lilly AI platform; small biotech, no deal value disclosed, so impact unclear.
Also known as: Genome&Company / 지놈앤컴퍼니 / 314130 / KRX:314130
Source: KRX statistical information